Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A concise comparison answering Which Performs Better Index Fund Or Target Date Fund, focusing on performance, risk, and long-term suitability.
25,681 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
As of June 2026, households pursue financial independence by targeting $7,500 a month in dividend income to replace a...
A major biotech takeover bid sets the tone for today’s market. AbbVie’s cash offer for Apogee Therapeutics sent share...
Analysts convene Thursday to highlight key stock moves ahead of a holiday weekend, with fresh targets and cautions ac...
Two popular aerospace ETFs pick up very different signals from the sky. This guide explains why cost, exposure, and c...
As the world shifts toward cleaner power, investors face a choice: broad clean energy exposure or a focused nuclear a...
Micron Technology has stunned investors with a massive year-long rally. This article breaks down the drivers behind t...
I’m a fan of Costco as a retailer, but my investing stance is stubbornly conservative. Here’s the core reason haven't...
A provocative claim about AI and the economy has investors buzzing: could crash economy years? This article breaks do...
Energy markets moved on geopolitical headlines, lifting ConocoPhillips stock in intraday trading. This article explai...
When headlines shout that Bitcoin is dead, smart investors reset the math. Here’s a practical plan to invest $500 tod...
Joby Aviation delivers a strong Q1 showing and signals progress toward commercial passenger flights. In today’s stock...